Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)

Yale University30 enrolled

Overview

The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in hepatology clinics. There are many benefits of AUD treatment among patients with AUD and ALD such as reduction in liver-related complications and hepatology clinicians providing this care in an integrated fashion can improve access and uptake.

Study Type

INTERVENTIONAL

Allocation

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Enrollment

Conditions

Alcohol Use Disorder Alcohol-associated Liver Disease

Interventions

A multipronged intervention including hepatology clinician education, patient education, clinical decision support, and clinician audit and feedback which will be adapted and tested.

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Must provide care for patients with liver disease at a hepatology clinical location within the Yale School of Medicine and YNHH medical system. Exclusion Criteria: * Providers who do not treat patients with chronic liver disease and alcohol-associated liver disease.

Locations (1)

Yale School of Medicine/Yale-New Haven Health

New Haven, Connecticut, United States

RECRUITING

Outcomes

Primary Outcomes

Feasibility

Percentage of clinicians enrolled out of all recruited

Time frame: 12 months

Secondary Outcomes

Acceptability

Percentage of clinicians that attend the educational workshops and utilize implementation tools.

Time frame: 12 months

Central Contacts

Lamia Haque, MD MPH

CONTACT

(203) 777-0304 lamia.haque@yale.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.